Sign in
Taking people in United StatesPhase 2

Tests CIR-0602K in people with type 1 diabetes using automated insulin delivery

Tests the drug CIR-0602K against a placebo in adults with type 1 diabetes.

Key facts

Who runs it
University of Virginia
Where
Charlottesville, United StatesSee the site
Trial code
Registry title
Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
22 Feb 2026
Expected to end
Sept 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CIR-0602K
  • Placebo
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-45 with type 1 diabetes who use a closed-loop automated insulin delivery system. It tests the study drug CIR-0602K against a placebo for 12 weeks.

Age
18-45 years
Sex
All sexes can join.
Disease stage
Type 1 diabetes for at least one year, with HbA1c below 10% (86 mmol/mol). BMI 18-35 kg/m2, and either BMI of 25 or more or a total daily insulin dose of 0.5 units/kg/day or more.
Earlier treatment
Must use closed-loop AID therapy that works with a Dexcom G7 CGM. Must be on a stable regimen of non-diabetic medications for the last 6 months.
Biomarker or test result
All screening labs must be within normal limits or not clinically significant.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Smoked tobacco in the last two years
  • Known HIV
  • Using any blood sugar medication other than insulin, such as GLP-1 receptor agonists or SGLT2 inhibitors
  • Level 3 hypoglycemia or diabetic ketoacidosis in the last 12 months

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • History of type 1 diabetes for at least one year
  • Age 18-45 years
  • HbA1c <10%; BMI 18-35 kg/m2. Within this criterion, participants must have either BMI ≥25 or total daily insulin dose of ≥0.5 units/kg/day; Currently utilizing closed-loop AID therapy that is compatible with Dexcom G7 CGM; On stable regimen of non-diabetic medications for the last 6 months; All screening labs within normal limits or not clinically significant; Ability to take oral medication and be willing to adhere to the study drug/placebo for 12 weeks; For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 2 weeks after the end of CIR-0602K administration; For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study intervention; Agreement to adhere to Lifestyle Considerations throughout study duration

Who cannot take part

  • Current use of any antihyperglycemic medication beyond insulin (i.e., GLP-1 receptor agonists, SGLT2 inhibitors, etc.)
  • Daily use of anti-inflammatory medications (e.g., ibuprofen, aspirin, prednisone, dexamethasone, etc.)
  • History of hypersensitivity or prior adverse reaction to the study drug, closely-related compounds, or any of the stated ingredients
  • Use of concomitant medications with a known significant metabolism by CYP2C8 or CYP2C (including paclitaxel, phenytoin, warfarin, celecoxib, tolbutamide, or repaglinide) for the duration of the study
  • Participation in an investigational study (other than a non-treatment registry study) or received an investigational drug withing 30 days or 5 half-lives (whichever is longer) prior to randomization
  • History of smoking tobacco products within the last two years
  • History of alcohol abuse or illicit drug abuse within 6 months of screening
  • Known history of human immunodeficiency virus (HIV)
  • History of other significant disease (e.g., cardiac, cerebrovascular, gastrointestinal, liver, renal, or endocrine) that could, in the investigator's view, alter study outcomes
  • Any surgical or medical condition which may significantly alter the absorption of the study drug including but not limited to the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active inflammatory bowel syndrome
  • History of Level 3 hypoglycemia within the last 12 months
  • History of diabetic ketoacidosis (DKA) within the last 12 months
  • Screening electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease
  • Unstable doses (i.e., dose change within the last 4 months) of vasoactive medications (e.g., calcium-channel blockers, statins, angiotensin-converting enzyme inhibitors, diuretics, nitrates, alpha-blockers, beta-blockers, etc.)
  • Macroalbuminuria (i.e., urine albumin: creatinine >300 mg per g)
  • Current Pregnancy or currently breastfeeding
  • Diagnosis of peripheral neuropathy (assessed by screening monofilament exam)
  • Retinopathy beyond mild, nonproliferative retinopathy
  • Screening oxygen saturation <90%

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

Where in United States

  • University of VirginiaCharlottesville, United StatesContact: Horton B Horton, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.

The 2 groups in the trial

  • CIR-0602KExisting treatment, for comparison

    CIR-0602K 250 mg daily

  • PlaceboPlacebo, for comparison

    Matching Placebo Tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of a Novel Insulin Sensitizer on Glycemic Control, Insulin Usage, and Cardiovascular Biomarkers in People With Type 1 Diabetes Who Use Closed-loop Automated Insulin Delivery
Plain-language title
Tests CIR-0602K in people with type 1 diabetes using automated insulin deliveryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07186660, who can take part
Record updated
25 February 2026